Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Amgen, bone mineral
Amgen dismisses bone density concerns related to its weight-loss drug
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after those concerns wiped off more than $12 billion from the company's market value.
Amgen defends obesity drug amid bone concerns
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and has asked the journal to issue a correction and add in the finalized data.
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug. On Wednesday, Amgen Inc (NASDAQ:AMGN) stated the MariTide (maridebart cafraglutide,
1d
What’s Happening With Amgen Stock?
In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...
1d
Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?
Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...
STAT
2d
A scrap of data on Amgen’s obesity drug candidate wipes out $12 billion in market value
On Tuesday, a tiny shred of data on
Amgen
’s lead obesity candidate — not yet verified — erased $12 billion in market value.
23h
Signal Says Pharma Stock Selloff Should Be Over
Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday.
6h
What Analysts Are Saying About Amgen Stock
Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a ...
1d
Amgen slips as Cantor cites safety concerns linked to obesity candidate
Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...
Hosted on MSN
1d
Amgen dismisses bone density concerns related to its new weight-loss drug
(Reuters) -
Amgen
said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, ...
1h
Evercore ISI Remains a Buy on Amgen (AMGN)
In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Amgen (AMGN – Research Report). The company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
NASDAQ
MariTide
AstraZeneca
bone density
Eli Lilly and Company
Feedback